Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of roflumilast on exacerbation rate in patients with COPD
2005-003937-42Phase 3Completed
- Sponsor
- Altana Pharma
- Start
- Dec 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of roflumilast in chronic obstructive pulmonary disease (COPD), sponsored by Altana Pharma. Primary endpoint: COPD exacerbation rate. Started Dec 2005; status: completed.
02
Drugs
roflumilast
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2005-003937-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003937-42.